Collplant Biotechnologies vs Oramed Pharmaceuticals
Collplant Biotechnologies is the larger business, with $2.4m of revenue in fiscal 2025 against $2.0m for Oramed Pharmaceuticals (1.2 times as much). Collplant Biotechnologies grew faster (360.4% against 49.3%). Oramed Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 3202.5% against -484.6%. Collplant Biotechnologies carries less debt relative to equity (0.0% against 0.3%).
| Latest fiscal year | Collplant BiotechnologiesCLGN, 2025 | Oramed PharmaceuticalsORMP, 2025 |
|---|---|---|
| Revenue | $2.4m | $2.0m |
| Revenue growth | 360.4% | 49.3% |
| Net income | −$11.5m | $64.0m |
| Operating margin | -484.3% | -754.4% |
| Net margin | -484.6% | 3202.5% |
| Return on equity | -117.6% | 35.2% |
| Free cash flow | −$9.4m | −$9.2m |
| Cash | $5.6m | $45.9m |
| Total debt | $0 | $652,000 |
| Debt to equity | 0.0% | 0.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $4.7m |
| Employees | — | — |
| Market value | $52.2m | $165m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 4 sales |